The present invention relates to a composition comprising at least one human milk oligosaccharide and/or a precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants or young children born by C-section.

The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.

The present disclosure generally relates to methods of preparing protein hydrolysates for use in pediatric nutritional compositions. Specifically, alpha-, beta- and/or kappa casein enriched casein, acid casein or caseinates can be hydrolyzed with proteases such as trypsin (trypsin-like), chymotrypsin (chymotrypsin-like), pepsin and/or plasmin to produce a hydrolysate that is close to the peptide composition of human breast milk.

A combination of scyllo-inositol and myo-inositol, wherein, the scyllo-inositol and myo-inositol are nutritional ingredients for use in the prevention or treatment of a condition selected from the group consisting of prediabetes, type II diabetes, gestational diabetes mellitus and a condition associated with any of the forgoing in a subject, and a composition comprising scyllo-inositol and myo-inositol.

The present invention provides a method of controlling growth of unwanted microorganisms by limiting their access to manganese. More specifically, the present invention provides a method of inhibiting or delaying growth of yeast and mold by reducing the manganese concentration in a product which is preferably a food product. The invention also provides manganese scavengers and uses thereof to inhibit or delay fungal growth. The manganese scavenger may be a bacterial cell, specifically a lactic acid bacterial cell, more specifically Lactobacillus rhamnosus alone or in combination with Lactobacillus paracasei.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

The present invention relates to a composition for producing a fermented milk product showing a low degree of post-acidification during storage comprising ⋅ 1) a starter culture of lactic acid bacteria comprising at least one lactose-deficient Streptococcus thermophilus strain, which is capable of metabolizing a non-lactose carbohydrate, and at least one lactose-deficient Lactobacillus delbrueckii subsp. bulgaricus strain, which is capable of metabolizing the non-lactose carbohydrate, and ⋅ 2) a probiotic strain selected from the group consisting of Lactobacillus strain and a Bifidobacterium strain.

The present invention relates to a composition for producing a fermented milk product showing a low degree of post-acidification during storage comprising ⋅ 1) a starter culture of lactic acid bacteria comprising at least one lactose-deficient Streptococcus thermophilus strain, which is capable of metabolizing a non-lactose carbohydrate, and at least one lactose-deficient Lactobacillus delbrueckii subsp. bulgaricus strain, which is capable of metabolizing the non-lactose carbohydrate, and ⋅ 2) a probiotic strain selected from the group consisting of Lactobacillus strain and a Bifidobacterium strain.